Assessment of Needs
The IAS–USA offers this state-of-the-art activity on the evolving challenges of managing HIV disease as part of a nationwide continuing medical education (CME) effort for physicians. Despite the availability of 29 US Food and Drug Administration-approved antiretroviral drugs in 6 mechanistic classes, additional drugs for the treatment of HIV infection are necessary. Important properties of investigational HIV drugs are virologic activity (especially against drug-resistant viruses), efficacy, and adherence. Investigational drugs in existing classes include the nucleoside analogue reverse transcriptase inhibitor EFdA, the nonnucleoside analogue reverse transcriptase inhibitor doravirine, and the integrase strand transfer inhibitors bictegravir and cabotegravir. Investigational drugs in new classes include the attachment inhibitor fostemsavir and the entry inhibitor ibalizumab. Continued advances in HIV treatment will result from further development of these compounds.
At the conclusion of this webinar, participants will be able to:
- Identify investigational new HIV drugs in existing classes
- Identify investigational new HIV drugs in new classes
- Identify regimens for treatment-experienced patients using investigational new drugs
Who Should Attend
This webinar is designed for clinicians who have solid, working knowledge of HIV transmission, screening, and management, and who are actively treating patients with HIV infection.
This activity is also relevant for other practitioners, including nurse practitioners and other nursing professionals, physician assistants, and pharmacists.
Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.
Registration closes on Monday,January 30, 2017, 4:00 PM (PT).
Certificates will be available after the completion of the evaluation and claim form.
For more information or questions, please contact the registration department at firstname.lastname@example.org or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is eligible for ANCC credit, see final CNE activity announcement for specific details.
This activity is eligible for ACPE credit, see final CPE activity announcement for specific details.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at email@example.com or 415-544-9400.